Oncohematología y Genética

Unidad de Gestión Clínica de Oncología del HUVR

Luis de la Cruz Merino
Luis de la Cruz Merino

Luis de la Cruz Merino

Volver al programa
  1. Miembros del grupo
  2. Áreas de trabajo
  3. Publicaciones

Grupo: Unidad de Gestión Clínica de Oncología del HUVR

Directorio
Foto no disponible
  • de la Cruz Merino, Luis.Doctor en Medicina

Áreas de trabajo

Revistas Internacionales
Majem, M; Garcia-Martinez, E; Martinez, M; Munoz-Couselo, E; Rodriguez-Abreu, D; Alvarez, R; Arance, A; Berrocal, A; de la Cruz-Merino, L; Lopez-Martin, JA
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
CLINICAL & TRANSLATIONAL ONCOLOGY
Perez-Ruiz, E; Jimenez-Castro, J; Berciano-Guerrero, MA; Valdivia, J; Estalella-Mendoza, S; Toscano, F; Artacho, MRD; Garrido-Siles, M; Martinez-Bautista, MJ; Roldan, RV; Rivas-Ruiz, F; Nogales-Fernandez, E; Morales, C; Perez-Valderrama, B; De la Cruz-Merino, L; Rueda, A
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
CLINICAL & TRANSLATIONAL ONCOLOGY
Ascierto, PA; Del Vecchio, M; Mandala, M; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, MO; Maio, M; Middleton, MR; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, A; Fecher, LA; Millward, M; Khushalani, NI; Queirolo, P; Lobo, M; de Pril, V; Loffredo, J; Larkin, J; Weber, J
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
LANCET ONCOLOGY
Slamon, DJ; Neven, P; Chia, S; Fasching, PA; De Laurentiis, M; Im, SA; Petrakova, K; Bianchi, GV; Esteva, FJ; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Pivot, X; Sondhi, M; Wang, YB; Chakravartty, A; Rodriguez-Lorenc, K; Taran, T; Jerusalem, G
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE
Garcia, FJV; Carrion, NP; de la Cruz-Merino, L
Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2-overexpressing breast cancer Case report
MEDICINE
Martin, M; Guerrero-Zotano, A; Montero, A; Jara, C; Filipovich, E; Rojo, F; Moreno, F; Garcia-Saenz, JA; Ales, JE; Chacon, JI; Cruz, J; Gimenez, J; Cruz-Merino, L; Algara, M; Santisteban, M; Tarruella, SL
GEICAMGuidelines for the Management of Patients with Breast Cancer During theCOVID-19 Pandemic in Spain
ONCOLOGIST
Sanegre, S; Lucantoni, F; Burgos-Panadero, R; de La Cruz-merino, L; Noguera, R; Naranjo, TA
Integrating the Tumor Microenvironment into Cancer Therapy
CANCERS
Pascual, T; Cejalvo, JM; Oliveira, M; Vidal, M; Vega, E; Ganau, S; Julve, A; Zamora, E; Miranda, I; Delgado, A; Bermejo, B; de la Cruz- Merino, L; Juan, M; Ferrero-Cafiero, JM; Canes, J; Gonzalez, X; Villagrasa, P; Prat, A
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer
FUTURE ONCOLOGY